On this page
Quick Reference
Overview and Recommendations
Background
- •Understand the pathophysiology as a multi-stage cascade beginning with calcium dysregulation in pancreatic acinar cells. This leads to the premature conversion of trypsinogen to active trypsin, causing cellular autodigestion and the release of damage-associated molecular patterns (DAMPs) that trigger (SIRS).
- •Distinguish between the two clinical phases of the disease: the Early Phase (first week), dominated by the host's systemic inflammatory response and potential early organ failure, and the Late Phase (beyond one week), characterized by local complications such as peripancreatic fluid collections and persistent systemic inflammation.
- •Classify severity using the Revised Atlanta Classification (RAC), which categorizes AP into Mild (no organ failure or complications), Moderately Severe (transient organ failure < 48 hours or local/systemic complications), and Severe (persistent organ failure > 48 hours).
- •Identify the primary etiologies, noting that and biliary sludge account for 40–60% of cases, while alcohol consumption accounts for 20–30%. Metabolic triggers, specifically , become a critical risk when serum levels exceed 1,000 mg/dL (11.3 mmol/L).
- •Recognize the "Enigmatic Triad" of (DKA), hypertriglyceridemia, and acute pancreatitis, where each condition can potentially precipitate the others, complicating the initial diagnostic and metabolic stabilization efforts.
- •Note morphological variants including Interstitial Edematous Pancreatitis (IEP), characterized by diffuse enlargement without necrosis, and Necrotizing Pancreatitis, which involves tissue death of the parenchyma or peripancreatic tissues and carries a higher risk of infection.
Evaluation
- •Suspect acute pancreatitis in any patient presenting with sudden-onset, constant, and severe epigastric pain that often radiates to the back and is described as "boring" or "stabbing." Nausea and vomiting are nearly universal and typically do not relieve the pain.
- •Ask about specific risk factors including alcohol intake, history of symptomatic , recent procedures, and medications such as , , or (gliptins).
- •Examine the patient for signs of SIRS, specifically monitoring for tachycardia (HR > 90 bpm), tachypnea, and fever. Persistent tachycardia over the first 7 days is a strong predictor of mortality and infectious pancreatic necrosis.
- •Perform a thorough abdominal exam to identify guarding or rebound tenderness, which may suggest necrotic collections or an . Look for rare hemorrhagic signs like Cullen’s sign (periumbilical ecchymosis) or Grey Turner’s sign (flank ecchymosis).
- •Order a serum lipase level immediately; a value ≥ 3 times the upper limit of normal is highly suggestive of AP. Note that amylase is less specific and may return to normal more quickly than lipase.
- •Obtain a complete metabolic panel and lipid profile to screen for and assess renal function (creatinine) and liver enzymes (ALT > 150 U/L suggests a biliary etiology).
- •Calculate the Neutrophil-to-Lymphocyte Ratio (NLR) at admission and at 48 hours; a rising or persistently elevated NLR is a low-cost marker for predicting persistent organ failure.
- •Monitor for "Red Flags" indicating the need for ICU escalation, including hypotension unresponsive to initial fluids, altered mental status, or respiratory distress (FVC < 15 mL/kg or rising oxygen requirements).
- •Utilize the Modified Marshall Scoring System to objectively define organ failure across the respiratory (PaO2/FiO2 ratio), renal (serum creatinine), and cardiovascular (systolic blood pressure) systems.
- •Order a contrast-enhanced computed tomography (CECT) scan only if the diagnosis is uncertain or if the patient fails to improve after 48–72 hours, as early imaging may underrepresent the extent of pancreatic necrosis.
- •Screen for on the extensor surfaces of the extremities if hypertriglyceridemic pancreatitis is suspected, and assess for which correlates with worse clinical outcomes.
Management
- •Administer aggressive fluid resuscitation with isotonic crystalloids (Lactated Ringer's is often preferred) at 250–500 mL/h initially, unless cardiovascular or renal contraindications exist. Frequent reassessment of fluid status every 6–12 hours is mandatory to avoid fluid overload.
- •Initiate early enteral nutrition (oral or tube feeding) within 24 hours if tolerated, as it maintains the intestinal barrier and reduces the risk of bacterial translocation and infected necrosis compared to parenteral nutrition.
- •Manage pain aggressively using intravenous opioids (e.g., hydromorphone or fentanyl) or multimodal analgesia; avoid relying solely on NSAIDs in the acute phase due to renal risks.
- •Avoid prophylactic antibiotics in patients with sterile necrosis; antibiotics should be reserved for suspected or confirmed infected necrosis (e.g., new fever, rising WBC, or gas on CT).
- •Administer carbapenems (e.g., Meropenem 1g IV every 8 hours) or quinolones with metronidazole if infected necrosis is confirmed, as these agents have superior pancreatic tissue penetration.
- •Implement the "Step-Up" approach for infected pancreatic necrosis: start with percutaneous or endoscopic ultrasound-guided transluminal drainage (EUS-TD) before considering minimally invasive necrosectomy.
- •Utilize lumen-apposing metal stents (LAMS) for the drainage of walled-off necrosis (WON) to improve drainage efficiency and facilitate early nutritional recovery.
- •Treat severe (TG > 1,000 mg/dL) with an insulin infusion (0.1 units/kg/hour) or plasmapheresis to rapidly lower lipid levels and prevent further acinar injury.
- •Perform a during the same admission for all patients with mild biliary pancreatitis to prevent recurrent attacks; for severe cases, delay surgery until inflammatory collections have stabilized.
- •Monitor Procalcitonin (PCT) levels; a value > 1.0 ng/mL is highly suggestive of pancreatic necrosis and may guide the decision for invasive sampling.
- •Initiate Pancreatic Enzyme Replacement Therapy (PERT) (e.g., Creon 25,000–50,000 units per meal) in patients showing signs of malabsorption or those recovering from necrotizing pancreatitis to manage exocrine insufficiency.
- •Refer patients with persistent organ failure, extensive necrosis, or complex local complications to a tertiary specialized center early (within 24–48 hours) to reduce the risk of progression to SAP.
- •Monitor for pancreatic encephalopathy, characterized by confusion or neurological deficits, which may result from the systemic release of pancreatic enzymes like phospholipase A2.
- •Discharge patients once pain is controlled with oral medications, they can tolerate an oral diet, and systemic inflammatory markers are trending downward. Ensure a follow-up plan for repeat imaging if local collections were present.
Board Review — High Yield
- •Cullen's sign — Periumbilical ecchymosis indicating retroperitoneal hemorrhage/hemorrhagic pancreatitis.
- •Grey Turner's sign — Flank ecchymosis associated with severe necrotizing pancreatitis.
- •Sentinel Loop — A localized ileus of a jejunal loop seen on abdominal X-ray near the inflamed pancreas.
- •Revised Atlanta Classification — Defines severity based on organ failure duration: transient (<48h) vs persistent (>48h).
- •Hypertriglyceridemia — AP risk increases significantly when serum triglycerides exceed 1,000 mg/dL.
- •Step-up approach — The strategy of using percutaneous/endoscopic drainage before surgical necrosectomy for infected necrosis.
- •Pancreatic Encephalopathy — Neurological symptoms caused by circulating pancreatic enzymes and cytokine-mediated neuroinflammation.
- •Iatrogenic triggers — Post-ERCP pancreatitis is a common complication; risk is higher in patients with intrapancreatic fat deposition.
Deep Dive — Evidence Details
Definition, Synonyms, and Classification
- ▸The Revised Atlanta Classification distinguishes severity based on the duration of organ failure, with a critical threshold of 48 hours for defining 'persistent' failure.
- ▸Post-pancreatectomy acute pancreatitis (PPAP) is a distinct clinical entity requiring sustained postoperative hyperamylasemia for at least 48 hours.
- ▸Fatty pancreas is now the internationally recommended term to describe all forms of pancreatic fat accumulation, which may influence AP risk and severity.
Acute pancreatitis (AP) is an acute inflammatory process of the pancreas characterized by the premature activation of digestive enzymes within the acinar cells, leading to autodigestion of the gland and potentially triggering a systemic inflammatory response [7][18]. While the clinical course is often self-limiting, approximately 20% of patients develop a severe form associated with significant morbidity and mortality [17][18].
Synonyms and Alternate Names
Historically, various terms were used to describe the morphological and clinical stages of the disease. Modern nomenclature has been standardized to improve clinical communication and research consistency.
- Also Called: Acute pancreatic inflammation, acute pancreatic necrosis (when necrosis is present), hemorrhagic pancreatitis (historical term for severe cases).
- Post-Surgical Variants: Post-pancreatectomy acute pancreatitis (PPAP), postoperative pancreatitis (POP) [14]D[20]D.
- Specialized Terms: Fatty pancreas (standardized term for pancreatic fat accumulation) [1], acute on chronic pancreatitis (ACP) [15].
Key Definitions and Phases
The clinical progression of acute pancreatitis is divided into two distinct phases, which dictate priorities and prognostic assessments [12].
- Early Phase: Occurs within the first week of symptom onset. During this phase, the clinical picture is dominated by the host's systemic inflammatory response to local pancreatic injury. Systemic Inflammatory Response Syndrome (SIRS) is common and may lead to early organ failure [12][17].
- Late Phase: Extends beyond the first week and may last for weeks or months. This phase is characterized by local complications (e.g., peripancreatic fluid collections) and the persistence of systemic signs of inflammation or organ failure [12].
- Nadir: The point of maximal physiological derangement, often coinciding with the peak of inflammatory markers such as C-reactive protein (CRP) or YKL-40 [11].
- Plateau: A period of clinical stability where organ dysfunction neither improves nor worsens significantly.
- Recovery: The resolution of systemic inflammation and the gradual restoration of pancreatic function, though patients remain at risk for early-onset diabetes if hyperglycemia was present during the acute event [19]D.
Classification of Severity
The Revised Atlanta Classification (RAC) is the global standard for grading AP severity, relying on the presence of organ failure and local or systemic complications [12][17]. Organ failure is typically defined using the Modified Marshall Scoring System, focusing on the respiratory, cardiovascular, and renal systems.
Protocol for Severity Grading
Clinicians should follow these steps to classify the severity of an AP episode:
- Step 1: Assess for Organ Failure. Evaluate the patient for respiratory (PaO2/FiO2), renal (serum creatinine), and cardiovascular (systolic blood pressure) dysfunction [17].
- Step 2: Determine Duration. Monitor the duration of any identified organ failure. Failure that resolves within 48 hours is termed "transient," while failure lasting longer than 48 hours is "persistent" [12][17].
- Step 3: Identify Complications. Screen for local complications (e.g., acute fluid collections, necrosis) or systemic complications (exacerbation of pre-existing comorbidities like or chronic lung disease) [5][12].
- Step 4: Assign Grade. Categorize the patient into Mild, Moderately Severe, or Severe AP based on the findings from Steps 1-3 [17].
Morphological Classification
Based on contrast-enhanced computed tomography (CECT) findings, AP is classified into two morphological types:
- Interstitial Edematous Pancreatitis (IEP): Characterized by diffuse or localized enlargement of the pancreas due to inflammatory edema. The parenchyma enhances uniformly on CECT, and there is no evidence of tissue necrosis [12].
- Necrotizing Pancreatitis: Involves necrosis of the pancreatic parenchyma, peripancreatic tissues, or both. This variant is associated with a more protracted clinical course and higher risk of infection [12].
Clinical Variants and Associated Factors
Beyond the standard classification, several specific clinical variants exist, often defined by their unique etiology or surgical context.
| Severity Grade | Definition | Clinical Implications |
|---|---|---|
| Mild (MAP) | No organ failure; no local or systemic complications. | Usually resolves within one week; low mortality [17]. |
| Moderately Severe (MSAP) | Transient organ failure (<48h) and/or local/systemic complications. | May require prolonged hospitalization; low mortality if OF resolves [12][17]. |
| Severe (SAP) | Persistent organ failure (>48h) involving one or more organs. | High risk of mortality (36-50%); often requires ICU care [4][18]. |
| Variant Name | Key Distinguishing Feature | Associated Factors/Antibodies |
|---|---|---|
| Post-pancreatectomy (PPAP) | Occurs after pancreatic resection; requires sustained hyperamylasemia ≥48h [3][20]D. | Associated with postoperative pancreatic fistula (POPF) [13]D. |
| Hypertriglyceridemic (HTG-AP) | Triggered by serum triglycerides >500 mg/dL (5.6 mmol/L) [6]. | Often associated with obesity and poorly controlled diabetes [6]. |
| Acute on Chronic (ACP) | Acute episode superimposed on underlying chronic structural changes [15]. | Higher risk of endocrine/exocrine insufficiency [15]. |
| Drug-Induced | Triggered by specific medications (e.g., Azathioprine) [16]. | Azathioprine dose-independent hypersensitivity reaction [16]. |
| SLE-Associated | Rare gastrointestinal manifestation of [5]. | May require corticosteroids or immunosuppressants [5]. |
| IGB-Induced | Occurs following intragastric balloon insertion for weight loss [10]. | Potential mechanical compression or ductal obstruction [10]. |
Etiology and Triggering Factors
- ▸Hypertriglyceridemia-induced AP (HTG-AP) requires triglyceride levels typically >1,000 mg/dL and involves toxic free fatty acid release and hyperviscosity.
- ▸Microlithiasis triggers AP not just through obstruction, but via a novel NLRP3 inflammasome-mediated 'acute papillitis'.
- ▸The 'enigmatic triad' of DKA, HTG, and AP represents a high-risk metabolic state where the primary trigger is often difficult to isolate.
Acute pancreatitis (AP) is primarily driven by the premature activation of zymogens within pancreatic acinar cells, leading to autodigestion of the gland and a subsequent systemic inflammatory response. While the clinical presentation is often uniform, the underlying triggers are diverse, ranging from mechanical obstruction and metabolic derangements to genetic mutations and iatrogenic injury. Identifying the specific etiology is critical, as it dictates the risk of recurrence and guides long-term preventative strategies [39]D, [48].
Biliary and Mechanical Obstruction
Biliary disease remains the most common cause of AP globally, particularly in elderly populations [41]D. The classic mechanism involves the transient or persistent obstruction of the pancreatic duct by or biliary sludge, which increases ductal pressure and triggers acinar cell injury.
- Gallstones and : Large stones (>1 cm) typically cause obstruction at the ampulla of Vater [32]D. In pregnant patients, biliary AP is a significant concern, though small stones may spontaneously pass or disappear postpartum [32]D.
- Microlithiasis and Sludge: Even in the absence of macroscopic stones, microlithiasis (crystals <3 mm) can precipitate AP. Recent evidence suggests a novel mechanism: NLRP3 inflammasome activation. Cholesterol monohydrate and calcium bilirubinate crystals trigger the activation of macrophages in the papilla vateri, leading to "acute papillitis" and functional obstruction [35]D.
- Anatomical Variations: Congenital or acquired variations in the biliary and pancreatic ducts, such as or abnormal ductal junctions, are associated with an increased incidence of inflammatory conditions [36]D.
- Post-ERCP Pancreatitis (PEP): Iatrogenic injury during (ERCP) is a well-recognized trigger. Susceptibility to PEP is significantly increased in patients with intrapancreatic fat deposition (IPFD), which may exacerbate the local inflammatory response to procedural trauma [28].
Metabolic and Genetic Triggers
Metabolic disturbances, particularly those involving lipid metabolism, represent a growing proportion of AP cases, often presenting with higher severity [34]D.
- (HTG): This is the second or third most common cause, accounting for approximately 20% of cases in some regions [27]. AP risk increases significantly when serum triglycerides exceed 500 mg/dL (5.6 mmol/L), but the risk becomes critical at levels >1,000 mg/dL or 11.3 mmol/L [6], [33]D. The mechanism involves the breakdown of triglycerides by pancreatic lipase into toxic free fatty acids, which cause capillary damage and ischemia [24], [25]. Furthermore, extreme HTG can lead to hyperviscosity syndrome, further impairing pancreatic microcirculation [46]C.
- Genetic Syndromes: Severe HTG is often rooted in genetic defects such as Familial Chylomicronemia Syndrome (FCS). Mutations in the LPL (lipoprotein lipase) gene or the APOA5 gene (e.g., homozygous Q97X mutation) lead to impaired chylomicron clearance and recurrent AP episodes from infancy through adulthood [43]C, [45]C.
- The Enigmatic Triad: A complex interplay exists between Diabetic Ketoacidosis (DKA), HTG, and AP. In this triad, each condition can potentially precipitate the others, creating a diagnostic challenge in determining the primary trigger [44]C.
- Obesity and Steatosis: Beyond systemic lipids, local intrapancreatic fat is an independent risk factor for both the occurrence and severity of AP, likely due to the release of pro-inflammatory adipokines [28].
Alcohol and Substance-Related Causes
Alcohol consumption is a dominant etiology in younger populations [41]D. Chronic ethanol exposure sensitizes acinar cells to injury and alters ductal secretion, though the exact threshold for an acute flare varies by individual.
- Opioid-Induced Masquerade: A unique clinical challenge involves patients with chronic pancreatitis or recurrent flares who develop iatrogenic physiologic opioid dependence. In these cases, symptoms of can mimic the abdominal pain of an acute AP flare, leading to diagnostic confusion [31]C.
Drug-Induced Acute Pancreatitis (DIAP)
While rare, DIAP must be considered when other common causes are absent. Drugs are typically classified by the strength of evidence supporting their causality.
- Vincristine: Historically considered low-risk, recent pediatric data has identified vincristine monotherapy as a probable cause of AP (Naranjo score of 7), characterized by pancreatic edema and marked hyperenzymemia [47]C.
- Doxycycline: This tetracycline antibiotic has been infrequently but prospectively linked to AP, with symptoms typically appearing within the first week of therapy [49].
- L-asparaginase: Frequently associated with metabolic disturbances that secondary trigger AP in oncologic settings.
Infectious and Rare Etiologies
Infectious agents can cause direct acinar injury or secondary inflammation.
- Viral: , Coxsackie virus, and Hepatitis viruses.
- Parasitic: Ascaris lumbricoides can migrate into the pancreatic duct, causing mechanical obstruction.
- Autoimmune: (Type 1 and Type 2) involves IgG4-related or idiopathic duct-centric inflammation.
Etiology Summary Table
| Cause | Category | Frequency | Mechanism | Key Reference |
|---|---|---|---|---|
| Gallstones | Biliary | 40–60% | Ductal /obstruction | [32]D, [41]D |
| Alcohol | Toxic | 20–30% | Acinar sensitization/ductal plugs | [41]D |
| Hypertriglyceridemia | Metabolic | 10–20% | Free fatty acid toxicity/hyperviscosity | [6], [25], [27] |
| Microlithiasis | Biliary | Variable | NLRP3 inflammasome/papillitis | [35]D |
| ERCP | Iatrogenic | 2–10% | Mechanical/thermal/contrast injury | [28] |
| Genetic (FCS) | Metabolic | Rare | LPL or APOA5 deficiency | [43]C, [45]C |
| Vincristine | Drug-induced | Rare | Direct acinar toxicity | [47]C |
| Doxycycline | Drug-induced | Rare | Idiosyncratic reaction | [49] |
| Category | Specific Trigger | Pathogenic Mechanism |
|---|---|---|
| Mechanical | Gallstones, Sludge, Microlithiasis | Ductal obstruction, NLRP3 inflammasome activation [35]D |
| Metabolic | Hypertriglyceridemia (>11.3 mmol/L) | Lipolysis into toxic free fatty acids; hyperviscosity [24], [46]C |
| Iatrogenic | Post-ERCP | Mechanical trauma; exacerbated by intrapancreatic fat [28] |
| Genetic | LPL deficiency, APOA5 mutations | Impaired chylomicron clearance (FCS) [43]C, [45]C |
| Drug-Induced | Vincristine, Doxycycline | Direct acinar injury or idiosyncratic reactions [47]C, [49] |
| Combined | Mixed Etiology (e.g., Alcohol + HTG) | Synergistic acinar cell stress [39]D |
Pathophysiology
- ▸Sustained cytosolic calcium overload via Orai1 channels is the primary molecular trigger for premature zymogen activation and mitochondrial collapse.
- ▸The mode of acinar cell death (apoptosis vs. necroptosis/pyroptosis) is determined by mitochondrial ATP levels and dictates the severity of the systemic inflammatory response.
- ▸Severe acute pancreatitis involves multi-organ crosstalk, where intestinal barrier failure and the depletion of gut-derived acetate exacerbate systemic inflammation and organ dysfunction.
The pathogenesis of acute pancreatitis (AP) is a complex, multi-stage cascade that transitions from localized acinar cell injury to a systemic inflammatory response. The process is fundamentally driven by the premature activation of digestive zymogens within the pancreas, rather than the duodenum, leading to autodigestion of the gland [52]D[59]D. This cellular catastrophe is governed by calcium dysregulation, mitochondrial collapse, and a shift in the mode of regulated cell death (RCD) [54]D[60]D.
Phase 1: Intra-acinar Enzyme Activation and Calcium Signaling
The initiating event in AP involves the disruption of calcium (Ca²⁺) homeostasis within the pancreatic acinar cell. Under physiological conditions, Ca²⁺ signals are transient and localized. In AP, pathological triggers (e.g., , ethanol) induce sustained cytosolic Ca²⁺ elevation [59]D[62]D.
Step-by-step Mechanism of Initial Injury:
- Trigger Exposure: Toxic insults lead to excessive Ca²⁺ release from the endoplasmic reticulum via inositol trisphosphate (IP3) and ryanodine receptors [62]D.
- Store-Operated Calcium Entry (SOCE): Depletion of internal stores activates Orai1 channels, causing a sustained influx of extracellular Ca²⁺ [59]D.
- Zymogen Activation: This high Ca²⁺ concentration triggers the premature conversion of trypsinogen to active trypsin within intracellular compartments [52]D[59]D.
- Lysosomal Dysfunction: Trypsinogen and lysosomal hydrolases (e.g., cathepsin B) co-localize, further accelerating zymogen activation and disrupting autophagy [54]D.
Phase 2: Mitochondrial Dysfunction and Regulated Cell Death
Mitochondria serve as the central integrators of acinar cell fate. Sustained Ca²⁺ overload leads to the opening of the mitochondrial permeability transition pore (mPTP), resulting in the loss of mitochondrial membrane potential (ΔΨm) and the cessation of ATP production [54]D[60]D.
- ATP Depletion: The failure of mitochondrial oxidative phosphorylation leads to a critical drop in ATP levels. This energy failure determines the mode of cell death; while apoptosis requires ATP, its absence favors highly pro-inflammatory pathways like necroptosis and pyroptosis [54]D.
- Oxidative Stress: Mitochondrial dysfunction generates excessive reactive oxygen species (mtROS), which further damage cellular membranes and DNA [60]D.
- Pyroptosis: Mediated by gasdermin D (GSDMD), this inflammatory cell death pathway is exacerbated by the downregulation of anti-inflammatory cytokines like IL-37, which normally restrains NF-κB and MAPK signaling [52]D.
Phase 3: Local and Systemic Inflammatory Response
As acinar cells rupture, they release damage-associated molecular patterns (DAMPs) and activated enzymes into the interstitium, recruiting innate immune cells. This stage marks the transition to Systemic Inflammatory Response Syndrome (SIRS) [53]D[64]D.
- Cytokine Storm: Pro-inflammatory mediators such as TNF-α, IL-6, and IL-17 are upregulated, while protective mediators like IL-35 and IL-22 attempt to limit the damage [52]D[61]D. IL-35 functions through STAT1/STAT4 signaling to suppress Th1/Th17 differentiation [52]D.
- Immune Indices: The severity of this response can be monitored via the Systemic Immune-inflammation Index (SII) and the Neutrophil-to-Lymphocyte Ratio (NLR), which reflect the balance between systemic inflammation and immune exhaustion [55][56].
- Procalcitonin (PCT): While often associated with infection, PCT is significantly elevated in sterile AP due to the massive systemic release of cytokines [50].
Phase 4: Organ Crosstalk and Multi-Organ Dysfunction (MODS)
Severe AP (SAP) is characterized by the failure of distant organs, driven by the "gut-pancreas," "heart-pancreas," and "pancreas-brain" axes [53]D[63]D[65]D.
- Intestinal Barrier Failure: SAP induces gut microbiota dysbiosis, characterized by a depletion of beneficial taxa like Bifidobacterium pseudolongum [67]D. The resulting loss of acetate—a metabolite that normally inhibits M1 macrophage polarization via GPR43—leads to increased intestinal permeability and bacterial translocation [67]D[69]D.
- Cardiovascular and Renal Impact: Systemic inflammation and fluid sequestration lead to hypovolemia and myocardial depression. A link exists between heart failure with preserved ejection fraction (HFpEF) and pancreatic ischemia, where SIRS-induced injury promotes cardiac arrhythmias and congestion [53]D[68]D.
- Pancreatic Encephalopathy (PE): This neurological complication arises from blood-brain barrier disruption caused by circulating pancreatic enzymes (e.g., phospholipase A2) and cytokine-mediated neuroinflammation [63]D.
Susceptibility and Modulating Factors
Not all patients progress to SAP, suggesting significant immunogenetic and environmental variability.
- Circadian Rhythms: Disruption of circadian genes (e.g., BMAL1) alters amino acid metabolism and promotes macrophage infiltration, significantly increasing AP risk [66]D.
- Metabolic Trajectory: Serum metabolomics indicate that the dynamic regulation of amino acid and lipid metabolism early in the disease course influences the transition from mild to severe forms [58].
| Mediator | Source/Target | Pathophysiological Role | Effect on Severity |
|---|---|---|---|
| IL-35 | Regulatory T/B cells | Suppresses Th1/Th17; inhibits TNF and IL-6 [52]D | Protective |
| IL-37 | Epithelial/Immune cells | Inhibits NF-κB and GSDMD-mediated pyroptosis [52]D | Protective (often low in AP) |
| IL-22 | Th17/ILCs | Promotes epithelial repair; can be pathogenic in late stages [61]D | Dual Role |
| TNF-α | Macrophages | Drives SIRS and acinar cell necroptosis [52]D[54]D | Pathogenic |
| Acetate | B. pseudolongum | Inhibits M1 macrophage polarization via GPR43 [67]D | Protective |
| Pathway | Key Molecular Drivers | Inflammatory Potential | Relation to ATP [54]D |
|---|---|---|---|
| Apoptosis | Caspases 3, 8, 9 | Low (Non-lytic) | ATP-dependent |
| Necroptosis | RIPK1, RIPK3, MLKL | High (Lytic) | ATP-independent |
| Pyroptosis | NLRP3, Caspase-1, GSDMD | Very High (Lytic) | ATP-independent |
| Ferroptosis | Iron, Lipid peroxidation | High | Variable |
History and Physical Examination
- ▸Pain is the cardinal symptom in >90% of cases, but elderly patients often present with atypical or less pronounced abdominal symptoms, leading to potential diagnostic delays.
- ▸Tachycardia is a critical dynamic predictor of severity; cumulative heart rate trajectories over the first week are more predictive of mortality and necrosis than isolated measurements.
- ▸Metabolic syndrome components, particularly obesity and hypertriglyceridemia, significantly worsen AP outcomes and should be screened for during the initial physical exam.
The clinical evaluation of (AP) requires a high index of suspicion, as the presentation can range from mild, self-limiting discomfort to catastrophic systemic collapse. Clinicians must prioritize identifying the cardinal symptom of abdominal pain while simultaneously screening for signs of organ dysfunction and underlying metabolic risk factors [70][71].
Presenting Symptoms
Abdominal pain is the hallmark of AP, present in approximately 90% of patients [77]. The classic description is a sudden-onset, constant, and severe epigastric pain that often radiates to the back. This radiation occurs because the pancreas is a retroperitoneal organ; however, the absence of back pain does not exclude the diagnosis.
- Onset and Progression: Pain typically reaches maximum intensity within 30 to 60 minutes. In contrast to the gradual progression seen in some inflammatory conditions, AP pain is often described as "boring" or "stabbing."
- Associated Symptoms: Nausea and vomiting are nearly universal and often provide no relief to the patient.
- Etiological Clues: The history should include a thorough review of medications, specifically the use of (gliptins) [82] or a history of recent endoscopic procedures like , which is a known trigger for postprocedural pancreatitis [72]. While long-term trials have largely dispelled concerns regarding and AP, they should still be noted in the medication history [78]D.
- Surgical History: A history of metabolic and bariatric surgery (MBS), such as Roux-en-Y gastric bypass (RYGB) or biliopancreatic diversion with duodenal switch (BPD/DS), increases the risk of AP due to rapid weight loss and altered anatomy [76].
Physical Examination Findings
The physical examination should be conducted systematically, focusing on hemodynamic stability and signs of local or systemic complications.
Hemodynamic Assessment
Vital signs are the most critical initial data points. Tachycardia is a common early finding in severe acute pancreatitis (SAP). Recent evidence suggests that the cumulative burden and dynamic trajectory of the heart rate (HR) over the first 7 days are superior to single-timepoint measurements for predicting mortality and infectious pancreatic necrosis [75].
Abdominal Examination
- Inspection: Look for abdominal distension, which may indicate an associated ileus. Rare but classic signs of hemorrhagic pancreatitis include Cullen’s sign (periumbilical ecchymosis) and Grey Turner’s sign (flank ecchymosis), though these typically appear 48–72 hours after onset.
- Palpation: Tenderness is usually localized to the epigastrium but may be generalized. Guarding and rebound tenderness suggest peritoneal irritation, potentially from necrotic collections or associated [73].
- Auscultation: Bowel sounds may be diminished or absent if a localized or generalized ileus has developed.
Systemic and Etiological Signs
- Pulmonary: Tachypnea or decreased breath sounds at the bases may indicate pleural effusions or the onset of (ARDS).
- Dermatological: In cases of hypertriglyceridemic pancreatitis, clinicians should look for eruptive xanthomas (small, yellow-orange papules) on the extensor surfaces of the extremities [80]D.
- Nutritional Status: Assess for sarcopenia or sarcopenic obesity (low muscle mass with high adiposity), as these phenotypes are associated with prolonged hospital stays and worse clinical outcomes [8].
Phenotypic Variants
The presentation of AP varies significantly based on the patient's age and underlying metabolic profile. Elderly patients, in particular, present a diagnostic challenge due to more frequent atypical presentations [41]D.
Red Flags
Certain findings during the initial encounter necessitate urgent escalation of care and consideration for intensive care unit (ICU) admission:
- Tachycardia (HR > 90 bpm): Especially when persistent, as it correlates with SAP and organ failure [75].
- Hypotension: Suggestive of significant third-space fluid loss or systemic inflammatory response syndrome (SIRS).
- Altered Mental Status: May indicate poor perfusion or metabolic encephalopathy.
- Respiratory Distress: Indicated by tachypnea or an FVC < 15 mL/kg (in the context of neuromuscular compromise) or more commonly in AP, a rising oxygen requirement suggesting pulmonary edema or effusion.
Atypical Presentations
Clinicians must be wary of "silent" or vague presentations that can delay diagnosis and treatment:
- The Elderly: Patients over age 65 often present with less pronounced abdominal symptoms. They are more likely to have biliary-related AP and frequently have multiple comorbidities (e.g., renal failure, cardiovascular disease) that mask or complicate the inflammatory response [41]D.
- Pediatric ALL Patients: Children undergoing treatment for (ALL) may develop AP as a component of a complex acute abdomen, which can be masked by steroid use or other chemotherapy-related side effects [73].
- Obese Patients: Obesity is an independent risk factor for SAP [79]D. In these patients, physical signs like guarding may be harder to elicit, and the inflammatory response may be more severe due to the pro-inflammatory state of excess adipose tissue [71][81].
| Variant | Key Features | Frequency/Context |
|---|---|---|
| Elderly (>65 years) | Atypical/vague symptoms; higher prevalence of biliary etiology; increased risk of organ failure [41]D. | Increasing with aging population |
| Obese/Metabolic Syndrome | Higher risk of SAP and mortality; associated with hypertriglyceridemia and saturated fatty acid toxicity [71][79]D[80]D. | ~25% of Western populations |
| Pediatric | Often associated with systemic illness (e.g., ALL) or trauma; early nutritional intervention is key [73][74]. | Rare but high morbidity |
| Post-Bariatric Surgery | Increased risk following RYGB or BPD/DS; may present with altered anatomy complicating ERCP [76]. | Increasing in MBS patients |
| Tool | Domain Assessed | Clinical Utility |
|---|---|---|
| Visual Analogue Scale (VAS) | Pain Intensity | Most common unidimensional tool used in RCTs [70]. |
| Numeric Rating Scale (NRS) | Pain Intensity | Simple 0–10 scale for rapid assessment [70]. |
| Modified Brief Pain Inventory (m-BPI) | Multidimensional (Intensity + Interference) | Evaluates how pain affects function and quality of life [70][77]. |
Supportive Care and Complication Management
- ▸Procalcitonin levels > 1.0 ng/mL are a critical threshold indicating pancreatic necrosis and the potential need for escalation [105].
- ▸The 'step-up' approach favors on-demand endoscopic necrosectomy over immediate intervention following initial drainage of infected WON [83].
- ▸Pancreatic exocrine insufficiency affects 22% of post-AP patients, necessitating long-term monitoring and PERT [84].
The of acute pancreatitis (AP) requires a dual focus on early risk stratification to prevent systemic deterioration and the targeted intervention of local complications. Severe acute pancreatitis (SAP) is characterized by persistent organ failure and high mortality, often necessitating prolonged intensive care unit (ICU) stays exceeding 14 days [91]. Early direct admission to tertiary specialized care is associated with a significant reduction in the risk of progressing to SAP (aOR 1.38) compared to delayed transfer [86].
Step 1: Early Risk Stratification and Monitoring
Immediate assessment within the first 24–48 hours is critical for identifying patients at risk for persistent organ failure (POF) and infected pancreatic necrosis (IPN) [85].
- Neutrophil-to-Lymphocyte Ratio (NLR): Measure NLR at admission and during the first 48 hours. An elevated NLR is a low-cost, first-line biomarker for predicting POF and mortality [85].
- Serum GAS6: Obtain serum Growth Arrest-Specific 6 (GAS6) levels within 24 hours of admission. GAS6 reflects the degree of pancreatic necrosis and is a highly specific biomarker for identifying SAP early [96]D.
- Procalcitonin (PCT): Monitor PCT levels to guide antibiotic therapy and detect necrosis. A PCT level > 0.5 ng/mL is an indicator of disease severity, while levels > 1.0 ng/mL are highly suggestive of pancreatic necrosis [105]D.
- Cytokine Profiling: Circulating IL-6 and Angiopoietin-2 (Ang-2) serve as early biomarkers of endothelial dysfunction and systemic inflammation, predicting the development of POF [89].
Step 2: Management of Local Fluid Collections
Local complications include acute peripancreatic fluid collections (APFC), pancreatic pseudocysts (PPC), acute necrotic collections (ANC), and walled-off necrosis (WON).
- Pseudocyst Prediction: In hypertriglyceridemic AP (HTG-AP), use specialized nomograms incorporating early admission indicators to predict PPC development [90]. Machine learning models using routine clinical data can also classify patients by PPC risk status [97]D.
- Drainage Thresholds: Intervention is generally reserved for symptomatic or infected collections. Endoscopic ultrasound-guided transluminal drainage (EUS-TD) is the preferred modality [95][103]D.
- Stent Selection: For WON, lumen-apposing metal stents (LAMS), such as the AXIOS stent, are frequently utilized. LAMS provide high drainage efficiency and have been shown to contribute to the early improvement of nutritional status, specifically increasing the Prognostic Nutritional Index (PNI) compared to plastic stents [95].
Step 3: The Step-Up Approach for Infected Necrosis
Infected pancreatic necrosis (IPN) occurs in approximately 30% of patients with necrotizing pancreatitis and carries a mortality rate of 15%–35% [100]D. Management follows a "step-up" protocol.
- Initial Drainage: Perform EUS-guided drainage or percutaneous drainage for suspected or confirmed IPN [83].
- On-Demand Necrosectomy: After initial drainage, adopt an "on-demand" necrosectomy strategy. Randomized controlled trials indicate that immediate necrosectomy does not offer superior clinical success (defined as collection diameter < 3 cm) compared to performing necrosectomy only when clinical improvement stalls after drainage [83].
- Biliary Management: If biliary obstruction is present, consider multi-hole self-expandable metallic stents (MH-SEMS) to maintain patency while minimizing the risk of stent-induced pancreatitis [101]D.
Step 4: Antimicrobial and Antifungal Stewardship
IPN is primarily driven by the translocation of enteric gut flora into necrotic tissue [87][100]D. Paired profiling has demonstrated high similarity between gut microbiota and necrotic drainage fluid [87].
- Antibiotic Selection: Use carbapenems or quinolones with metronidazole to cover enteric pathogens [100]D.
- MDR and Fungal Risk: Be vigilant for multidrug-resistant (MDR) bacteria and fungal infections (primarily Candida albicans), which are associated with prolonged ICU stays and prior broad-spectrum antibiotic use [94]C[102]D. Targeted antifungal therapy (e.g., fluconazole or echinocandins) is required if fungal IPN is confirmed via invasive sampling [94]C.
Step 5: Long-term Recovery and Exocrine Support
Survivors of AP are at high risk for pancreatic exocrine insufficiency (PEI) and unplanned readmission [84][98]D.
- Pancreatic Enzyme Replacement Therapy (PERT): PEI occurs in 22% of patients following AP [84]. Initiate PERT (e.g., Creon 25,000–50,000 units per meal) in patients with clinical signs of malabsorption or confirmed PEI to improve nutritional outcomes [84].
- Readmission Prevention: Use nomogram models to identify patients at high risk for 1-year unplanned readmission, focusing on those with severe initial disease or persistent local complications [98]D.
| Biomarker | Timing | Clinical Significance | Evidence Level |
|---|---|---|---|
| NLR | 24-48h | Predicts persistent organ failure and mortality [85] | 2a |
| GAS6 | < 24h | Specific marker for pancreatic necrosis and SAP [96]D | 5 |
| Procalcitonin | Serial | > 0.5 ng/mL: Severity; > 1.0 ng/mL: Necrosis [105]D | 5 |
| IL-6 / Ang-2 | Early | Predicts endothelial dysfunction and POF [89] | 2a |
| Stent Type | Key Features | Clinical Impact | Ref |
|---|---|---|---|
| LAMS (AXIOS) | Electrocautery-enhanced, large diameter | Improved nutritional status (PNI); high drainage efficiency | [88][95] |
| BFMS (NAGI) | Bi-flanged metal stent | Comparable technical success to LAMS | [88] |
| Plastic Stents | Traditional multi-pigtail | Lower nutritional improvement compared to LAMS | [95] |
References
- [1]
Vujasinovic M, Demir IE, Marchegiani G et al.. “International Multidisciplinary Consensus Report on Definitions, Diagnostic Criteria, and Management of Fatty Pancreas: A Joint Statement Endorsed by EPC, APA, EASD, EASL, ESGAR, ESGE, ESP, ESPCG, ESPEN, ESPGHAN, IAP, JPS, KPBA, LAPSG, and UEG.” United European gastroenterology journal (2026). PMID: 41689768 ↗
L1cGUIDELINECited in: Definition, Synonyms, and Classification - [2]
Adeniran EA, Jiang Y, Yadav D et al.. “Multiple substance use and the risk of pancreatitis: a systematic review.” Therapeutic advances in gastroenterology (2025). PMID: 40873658 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [3]
Heo D, Cardoso SA, Cardoso RP et al.. “Clinical implications of postoperative hyperamylasemia and postpancreatectomy acute pancreatitis after pancreatectomy: A systematic review and meta-analysis.” Surgery (2025). PMID: 40435914 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [4]
Kowal MR, Bhatnagar V, Pine J et al.. “Systematic review of peritoneal lavage and dialysis for patients with severe acute pancreatitis.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2025). PMID: 39939210 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [5]
Williamson L, Hao Y, Basnayake C et al.. “Systematic review of treatments for the gastrointestinal manifestations of systemic lupus erythematosus.” Seminars in arthritis and rheumatism (2024). PMID: 39461088 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [6]
Haseef M, Li SCH, Gaitt T et al.. “Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries.” Current opinion in endocrinology, diabetes, and obesity (2026). PMID: 41717773 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification, Etiology and Triggering Factors - [7]
Ibrahim MY, Alhaj MM, Ibrahim AAA et al.. “Association of platelet-lymphocyte ratio with acute pancreatitis severity: systematic review and meta-analysis.” BMC gastroenterology (2025). PMID: 41388444 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification - [8]
Kuzman M, Joseph N, Nafady R et al.. “Clinical Impact of Sarcopenia and Sarcopenic Obesity in Acute Pancreatitis: A Systematic Review.” ANZ journal of surgery (2026). PMID: 41351308 ↗
L2aSR_OBSCited in: Definition, Synonyms, and Classification, History and Physical Examination - [9]
Siuka D, Rakuša M, Vodenik A et al.. “Free and Bioavailable Vitamin D Are Correlated with Disease Severity in Acute Pancreatitis: A Single-Center, Prospective Study.” International journal of molecular sciences (2025). PMID: 40565159 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [10]
Yahia Y, Abuodeh J, Chandra P et al.. “Risk Factors for Acute Pancreatitis Following Intragastric Balloon Insertion: A 7-Year Retrospective Cohort Study.” Obesity surgery (2025). PMID: 39806256 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [11]
Blažević N, Trkulja V, Rogić D et al.. “YKL-40 as a risk stratification marker in acute pancreatitis: A prospective study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2025). PMID: 39638701 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [12]
Guilabert L, Cárdenas-Jaén K, Vaillo-Rocamora A et al.. “Normal saline versus lactated Ringer's solution for acute pancreatitis resuscitation, an open-label multicenter randomized controlled trial: the WATERLAND trial study protocol.” Trials (2024). PMID: 39434191 ↗
L2bTRIAL_NONRANDOMCited in: Definition, Synonyms, and Classification - [13]
Grudzińska E, Gajda M. “Postoperative Acute Pancreatitis After Pancreatic Resections-A Narrative Review and a Diagnostic Algorithm.” Cancers (2025). PMID: 40940873 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [14]
Sato A, Tani A, Mishima Y et al.. “Assessment of two different criteria for post-pancreatectomy acute pancreatitis: a single-center retrospective analysis and literature review.” HPB : the official journal of the International Hepato Pancreato Biliary Association (2025). PMID: 40340215 ↗
L5REVIEW_NARRATIVECited in: Definition, Synonyms, and Classification - [15]
Bouça-Machado T, Araújo Teixeira JP, Rebelo P et al.. “Comparison of acute pancreatitis and acute on chronic pancreatitis: a retrospective cohort study.” European journal of gastroenterology & hepatology (2025). PMID: 39976002 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [16]
Ranjan MK, Neupane P, Maharjan B et al.. “Adverse Events Related to Azathioprine Use in Patients With Inflammatory Bowel Disease: A Real-World Cohort Study.” Gastroenterology research and practice (2026). PMID: 41971243 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [17]
Zhou H, Li W, Yang S et al.. “Prediction of acute pancreatitis severity using NLR, procalcitonin, and CT severity score: A retrospective study.” Medicine (2025). PMID: 40629608 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [18]
Orbelian L, Trembach N, Durleshter V. “The Role of Inflammatory and Hemostatic Markers in the Prediction of Severe Acute Pancreatitis: An Observational Cohort Study.” Recent advances in inflammation & allergy drug discovery (2025). PMID: 39694959 ↗
L2bCOHORTCited in: Definition, Synonyms, and Classification - [19]
Dungan KM, Chinchilli VM, Pichardo-Lowden A et al.. “Hyperglycemia During Acute Pancreatitis and Progression to Early-Onset Diabetes After Recovery: Preliminary Findings From the Diabetes Related to Acute Pancreatitis and Its Mechanisms (DREAM) Study.” Diabetes care (2026). PMID: 41940812 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [20]
Poelsler LH, Bellotti R, Pably D et al.. “Analysis of Different Post-Operative Hyperamylasemia Criteria for Defining Post-Pancreatectomy Acute Pancreatitis After Distal Pancreatectomy-A Retrospective Single-Center Study.” Journal of clinical medicine (2026). PMID: 41827220 ↗
L5OTHERCited in: Definition, Synonyms, and Classification - [21]
Emara A, Mansour A, Aboeldahab H et al.. “Efficacy and Safety of Olezarsen in Hypertriglyceridemia: An Updated Meta-Analysis of Randomised Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 41943994 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [22]
Elbahloul MA, Gamal A, Maihoub O et al.. “Efficacy and Safety of Apolipoprotein C-III Inhibitors in Hypertriglyceridemia: A Network Meta-Analysis of Randomised Controlled Trials.” Diabetes, obesity & metabolism (2026). PMID: 41917770 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [23]
Rehman A, Rajdeep D, Mohnkern JD et al.. “Efficacy of Olezarsen in Severe Hypertriglyceridemia and Acute Pancreatitis Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Digestive diseases and sciences (2026). PMID: 41865223 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [24]
Peterson AL, Ashraf AP, Bachman J et al.. “Screening, Diagnosis, and Management of Pediatric Hypertriglyceridemia: A Scientific Statement From the American Heart Association.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41705332 ↗
L1cGUIDELINECited in: Etiology and Triggering Factors - [25]
Masood A, Qureshi AUH, Khalid Z et al.. “Efficacy and safety of antisense oligonucleotide therapies targeting APoC-III in patients with severe hypertriglyceridemia: a meta-analysis of randomized controlled trials.” Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace (2026). PMID: 41755797 ↗
L1aSR_MA_RCTCited in: Etiology and Triggering Factors - [26]
Loomba R, de-Madaria E, Afghani E et al.. “Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia-Results of a Post Hoc Analysis of the Phase 3 PALISADE Study.” Alimentary pharmacology & therapeutics (2026). PMID: 41923352 ↗
L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors - [27]
Qi S, Wang S, Chen W et al.. “Clinical outcomes of lipid apheresis in hypertriglyceridemia-induced acute pancreatitis: A 10-year triglyceride-stratified retrospective study.” Journal of clinical lipidology (2026). PMID: 41963121 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [28]
Cerbino B, Süffert LC, Monteiro A et al.. “Intrapancreatic Fat Deposition and Risk of Post-ERCP Pancreatitis: A Systematic Review and Meta-analysis.” Pancreas (2026). PMID: 41668341 ↗
L2aSR_OBSCited in: Etiology and Triggering Factors - [29]
Shi B, Feng J, Hu P et al.. “Clinical Outcomes and Safety of Ureteral Catheter-Assisted Antegrade Guidewire Intubation in the Laparoscopic-Endoscopic Rendezvous Procedure for Cholelithiasis with Choledocholithiasis: A Retrospective Cohort Study.” Therapeutics and clinical risk management (2026). PMID: 41859199 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [30]
Liu J, Xu H, Huang C et al.. “Admission HDL-C and recurrence risk of hypertriglyceridemia-induced acute pancreatitis: a multicenter cohort study.” Frontiers in nutrition (2026). PMID: 41693951 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [31]
Dayan-Rosenman D, Diletti-Swenson S, Ghayalod N et al.. “Iatrogenic physiologic opioid dependence masquerading as recurrent acute pancreatitis flares: case series.” Addiction science & clinical practice (2026). PMID: 41680940 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [32]
Maringhini A, Patti R, Maringhini M et al.. “Ursodeoxycholic Acid for the Prevention of Relapse of Pregnancy-Related Acute Gallstone Pancreatitis.” Journal of clinical medicine (2026). PMID: 41976880 ↗
L5OTHERCited in: Etiology and Triggering Factors - [33]
Deng F, Ding L, Du YY et al.. “Low-molecular-weight heparin and respiratory failure in hypertriglyceridemia-associated acute pancreatitis.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41968002 ↗
L5OTHERCited in: Etiology and Triggering Factors - [34]
Li Y, Wang Y, Wan X et al.. “Radiomics derived from MRI T2-weighted imaging combined with clinical variables for predicting disease severity in hypertriglyceridemic acute pancreatitis.” Abdominal radiology (New York) (2026). PMID: 41925844 ↗
L5OTHERCited in: Etiology and Triggering Factors - [35]
Sirtl S, Ahmad M, Allawadhi P et al.. “NLRP3 Inflammasome Activation-Induced Acute Papillitis as a Trigger of Acute Pancreatitis - A Novel Mechanism of Microlithiasis-Induced Acute Pancreatitis.” United European gastroenterology journal (2026). PMID: 41830600 ↗
L5OTHERCited in: Etiology and Triggering Factors - [36]
Ozkaya M, Atik I, Ozkaya S et al.. “Incidence and clinical significance of biliary and pancreatic duct variations on magnetic resonance cholangiopancreatography.” Abdominal radiology (New York) (2026). PMID: 41801378 ↗
L5OTHERCited in: Etiology and Triggering Factors - [37]
Faraci S, Rollo G, Alghisi F et al.. “ERCP-based management of pediatric chronic pancreatitis: Results from a retrospective long-term multicentric study.” Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2026). PMID: 41723027 ↗
L5OTHERCited in: Etiology and Triggering Factors - [38]
Liu Z, He Y, Chen Z et al.. “Pleural effusion within 24 h of admission predicts severe hypertriglyceridemia-induced acute pancreatitis and organ failure: retrospective cohort of 296 patients.” Frontiers in medicine (2026). PMID: 41658612 ↗
L5OTHERCited in: Etiology and Triggering Factors - [39]
Peng Q, Long Y, Yang K et al.. “Prognostic analysis of acute pancreatitis due to different etiologies and establishment and validation of an early prediction model.” Lipids in health and disease (2026). PMID: 41645226 ↗
L5OTHERCited in: Etiology and Triggering Factors - [40]
Spoială EL, Oltean C, Vasiliu I et al.. “Multimodal Management of Extreme Hypertriglyceridemia in a Child with Recurrent Pancreatitis: Clinical Challenges and Solutions.” Journal of clinical medicine (2026). PMID: 41598575 ↗
L5OTHERCited in: Etiology and Triggering Factors - [41]
Krajewska A, Tłustochowicz K, Kowalik A et al.. “Comparison of the Clinical Course, Management and Outcomes of Acute Pancreatitis in Aged and Young Patients.” Biomedicines (2026). PMID: 41595672 ↗
L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors, History and Physical Examination - [42]
Chiriac S, Sfarti C, Minea H et al.. “Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Bile Duct Stones-Avoiding the Avoidable.” Biomedicines (2026). PMID: 41595627 ↗
L5OTHERCited in: Etiology and Triggering Factors - [43]
Choudhary A, James A, Dahake U et al.. “Therapeutic plasmapheresis in a young infant with severe hypertriglyceridemia: a case report.” Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology (2026). PMID: 41923786 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [44]
Takasu S, Nakagawa M, Matsumoto S. “Autopsy case of a possible enigmatic triad accompanied by black esophagus and Wischnewsky spots.” Legal medicine (Tokyo, Japan) (2026). PMID: 41774981 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [45]
Vega J, Torres B, Maiz A et al.. “Case Report: Conventional therapy versus volanesorsen in two sisters with familial chylomicronemia syndrome.” Frontiers in nutrition (2026). PMID: 41737337 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [46]
Bodnar C, Hughey C, Bodker A et al.. “Milky Plasma, Murky Diagnosis: Urgent Plasma Exchange for Severe Hypertriglyceridemia-Induced Hyperviscosity Without Pancreatitis, but With Myocardial Infarction.” Journal of clinical apheresis (2026). PMID: 41709485 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [47]
Liu T, Cao Z, Lai F et al.. “Case Report: Vincristine-induced acute pancreatitis in pediatric Wilms tumor: first reported case challenging previous risk classifications and proposing vigilant monitoring protocols.” Frontiers in pediatrics (2025). PMID: 41602884 ↗
L4CASE_REPORTCited in: Etiology and Triggering Factors - [48]
Wang Z, Liu Y, Ren P et al.. “A prognostic model based on metabolic indicators for recurrent acute pancreatitis in hypertriglyceridemia patients: a retrospective cohort study.” Annals of medicine (2026). PMID: 41978916 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [49]
Gondal AN, Ahmed P, Akram F et al.. “Evaluation of Acute Pancreatitis in Patients Receiving Doxycycline Therapy: A Prospective Study.” Cureus (2026). PMID: 41646617 ↗
L2bCOHORTCited in: Etiology and Triggering Factors - [50]
Popa SL, Incze V, Ismaiel A et al.. “Non-Infectious Causes for Elevated Procalcitonin.” Medicina (Kaunas, Lithuania) (2026). PMID: 41901546 ↗
L2aSR_OBSCited in: Pathophysiology - [51]
Yang X, Zhang L, Lin H et al.. “Early oral anti-inflammatory diet in patients with mild acute pancreatitis: study protocol for a randomized controlled trial.” Trials (2026). PMID: 41668182 ↗
L2bTRIAL_NONRANDOMCited in: Pathophysiology - [52]
Yan H, Dang X, Du G et al.. “IL-35, IL-37, and IL-38 in acute pancreatitis: proposed immunopathogenic mechanisms and therapeutic potential.” Frontiers in immunology (2026). PMID: 41737213 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Supportive Care and Complication Management - [53]
Tun HN, Rahal O, Figueroa Baez IR et al.. “Heart failure with preserved ejection fraction beyond the heart: exploring the heart-liver-pancreas axis.” ESC heart failure (2026). PMID: 41711215 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [54]
Zhang J, Chen H, Wang Y et al.. “Cell death and its interaction with mitochondrial dysfunction in pathogenesis of acute pancreatitis: a comprehensive review.” Apoptosis : an international journal on programmed cell death (2026). PMID: 41663764 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [55]
Kurt SZE, Kurt E, Isin MS et al.. “The diagnostic value of the systemic immune-inflammation index in acute pancreatitis: a retrospective cohort study.” Irish journal of medical science (2026). PMID: 41926028 ↗
L2bCOHORTCited in: Pathophysiology - [56]
Ma H, Li N, Zhang H et al.. “The association between inflammatory indices and acute pancreatitis severity: a retrospective cohort study.” Frontiers in surgery (2026). PMID: 41835252 ↗
L2bCOHORTCited in: Pathophysiology - [57]
Chooklin S, Chuklin S. “Nanotherapy for acute pancreatitis: a systematic review of experimental strategies and mechanisms of action.” Discover nano (2026). PMID: 41661463 ↗
L2aSR_OBSCited in: Pathophysiology - [58]
Wang Y, Ma L, Jiang Y et al.. “Revealing the temporal metabolic trajectory and potential pharmacodynamic substances of Da-Cheng-Qi Decoction in treating patients with acute pancreatitis: A serum metabolomics-based study.” Journal of ethnopharmacology (2026). PMID: 41825726 ↗
L1bRCTCited in: Pathophysiology - [59]
Alsaleh T, George J. “Targeted therapeutics for pancreatitis.” Frontiers in physiology (2026). PMID: 41907532 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [60]
Chooklin S, Chuklin S. “Beyond Supportive Care: Mitochondria as a Strategic Therapeutic Avenue in Acute Pancreatitis.” Digestive diseases and sciences (2026). PMID: 41854947 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [61]
Chooklin S, Chuklin S. “Interleukin-22 in acute pancreatitis: Balancing damage and repair.” Hepatobiliary & pancreatic diseases international : HBPD INT (2026). PMID: 41763954 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [62]
Chooklin S, Chuklin S. “Breaking the Calcium Overload Cycle in Acute Pancreatitis: Emerging Pharmacological Strategies.” Digestive diseases and sciences (2026). PMID: 41703270 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [63]
Dai NN, Geng ZG, Wang J et al.. “Pancreas-brain axis: exploring the pathogenic mechanisms of pancreatic encephalopathy.” International immunopharmacology (2026). PMID: 41689875 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [64]
Feng X, Lin J. “Advances in Glucocorticoid Therapy for Acute Pancreatitis: A Review.” Pancreas (2026). PMID: 41677367 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [65]
Xu K, Han Y, Chen F et al.. “Dose-dependent dissociation between intestinal protection and pancreatic outcome following licochalcone A treatment in severe acute pancreatitis.” Frontiers in pharmacology (2026). PMID: 41971086 ↗
L5OTHERCited in: Pathophysiology - [66]
Li H, Zhang X, He Z et al.. “Disruption of the Circadian Rhythm Induces Acute Pancreatitis via Amino Acid Metabolism-Mediated Macrophage Infiltration.” Cellular and molecular gastroenterology and hepatology (2026). PMID: 41903683 ↗
L5OTHERCited in: Pathophysiology - [67]
Guan L, Li X, He C et al.. “Bifidobacterium Pseudolongum-Derived Acetate Attenuates Acute Pancreatitis Through GPR43-Mediated Suppression of M1 Macrophage Polarization.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 41903115 ↗
L5OTHERCited in: Pathophysiology - [68]
Uppal M, Neredimelli SK, Yadav HN et al.. “Development of an experimental model of severe acute pancreatitis with organ failure.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41881753 ↗
L5OTHERCited in: Pathophysiology, Supportive Care and Complication Management - [69]
Cheng L, Jiang C, Jiang W et al.. “Influences of probiotics plus enteral nutrition on intestinal flora and inflammatory response in patients with severe acute pancreatitis.” Frontiers in medicine (2026). PMID: 41877788 ↗
L5OTHERCited in: Pathophysiology - [70]
Joseph N, Kuhlmann L, Lucocq J et al.. “A Systematic Review of Pain Assessment Domains in Acute Pancreatitis Randomized Controlled Trials.” Pancreas (2026). PMID: 40748823 ↗
L1aSR_MA_RCTCited in: History and Physical Examination - [71]
Dobszai D, Obeidat M, Szalai EÁ et al.. “Metabolic syndrome components individually worsen the outcome of acute pancreatitis: a systematic review and meta-analysis.” Frontiers in endocrinology (2025). PMID: 41262260 ↗
L2aSR_OBSCited in: History and Physical Examination - [72]
Anderloni A, Spadaccini M, Binda C et al.. “Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial.” Gastroenterology (2026). PMID: 41511419 ↗
L1bRCTCited in: History and Physical Examination - [73]
Gan W, Zhang W, Cai J et al.. “A Multicenter Study of Acute Abdomen in Children With Acute Lymphoblastic Leukemia: CCCG-ALL-2015.” Cancer medicine (2025). PMID: 40842042 ↗
L1bRCTCited in: History and Physical Examination - [74]
Han Y, Zhao H, Fu L et al.. “The utilization of oral feeding in pediatric pancreatitis: a randomized controlled study.” Jornal de pediatria (2026). PMID: 41620210 ↗
L1bRCTCited in: History and Physical Examination - [75]
Wan J, Xiong S, Zou Y et al.. “Cumulative burden and dynamic trajectories of heart rate as predictors of prognosis in acute pancreatitis: an 18-year cohort study.” International journal of surgery (London, England) (2026). PMID: 40990508 ↗
L2bCOHORTCited in: History and Physical Examination - [76]
Kerbage A, Brunaldi VO, Al Annan K et al.. “Impact of Metabolic Surgery on the Severity and Outcomes of Acute Pancreatitis: A Retrospective Matched Cohort Study.” Obesity surgery (2025). PMID: 40804224 ↗
L2bCOHORTCited in: History and Physical Examination - [77]
Palermo TM, Ohls O, Dear B et al.. “Digital cognitive-behavioral therapy for pain management in individuals with recurrent acute and chronic pancreatitis (IMPACT-2): study protocol for a hybrid effectiveness-implementation trial.” Trials (2026). PMID: 41664170 ↗
L2bTRIAL_NONRANDOMCited in: History and Physical Examination - [78]
Jalleh RJ, Talley NJ, Horowitz M et al.. “The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.” The Journal of clinical investigation (2026). PMID: 41697736 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [79]
Tayier D, Wang K, Yuan Y et al.. “Research Status on the Effects of Obesity on Acute Pancreatitis.” Obesity reviews : an official journal of the International Association for the Study of Obesity (2026). PMID: 40751382 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [80]
Wang YX, Ge P, Chen HL. “Induction of hyperlipidemic pancreatitis by different fatty acids: A narrative review.” World journal of gastroenterology (2025). PMID: 40539203 ↗
L5REVIEW_NARRATIVECited in: History and Physical Examination - [81]
Zhu Q, Shan X, Tan D et al.. “Risk factor analysis and nomogram development for survival prediction in obese patients with severe acute pancreatitis: a retrospective study.” BMC gastroenterology (2025). PMID: 41013263 ↗
L2bCOHORTCited in: History and Physical Examination - [82]
Jaya Pragadeesh G, Abu Sali SA, Rajesh Kumar S et al.. “Gliptin induced acute pancreatitis: a literature review.” Acta gastro-enterologica Belgica (2025). PMID: 40504582 ↗
L2aSR_OBSCited in: History and Physical Examination - [83]
Mohamadnejad M, Hassanzadeh M, Anushirvani A et al.. “Immediate vs On-Demand Endoscopic Necrosectomy in Infected Walled-Off Pancreatic Necrosis: A Randomized Controlled Trial.” Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2026). PMID: 41722664 ↗
L1bRCTCited in: Supportive Care and Complication Management - [84]
Eperjesi O, Bucur M, Rancz A et al.. “Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41807143 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [85]
Chooklin S, Chuklin S. “Neutrophil-to-lymphocyte ratio for primary risk stratification in acute pancreatitis: a systematic review and meta-analysis.” Frontiers in medicine (2025). PMID: 41608433 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [86]
Ren Y, Xia L, Luo L et al.. “Early direct admission to tertiary hospital specialized care reduces risk of severe acute pancreatitis: A propensity score-matched retrospective cohort study.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41692636 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [87]
Xu X, He C, Ding L et al.. “The similarity between microbiota of gut and pancreatic necrotic drainage fluid in infected pancreatic necrosis and its potential diagnostic value: a prospective observational cohort study.” BMC microbiology (2026). PMID: 41612182 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [88]
Shahzil M, Faisal MH, Khan MH et al.. “Comparative efficacy and safety of bi-flanged metal stents versus lumen-apposing metal stents for endoscopic drainage of pancreatic fluid collections: a systematic review and meta-analysis.” European journal of gastroenterology & hepatology (2026). PMID: 41925047 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [89]
Shakeev K, Klyuyev D, Ogizbayeva A et al.. “Comparative Evaluation of the Prognostic Accuracy of IL-6 and Angiopoietin-2 for Early Severity Assessment in Acute Pancreatitis: A Systematic Review.” Diseases (Basel, Switzerland) (2026). PMID: 41590239 ↗
L2aSR_OBSCited in: Supportive Care and Complication Management - [90]
Qi R, Zhong J, Wang H et al.. “Nomogram for Predicting Pancreatic Pseudocyst in Hypertriglyceridemic Acute Pancreatitis: A Retrospective Cohort Study.” Journal of inflammation research (2026). PMID: 41982474 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [91]
Lew C, Jones M, Pham H et al.. “Outcomes of Patients With Severe Acute Pancreatitis Requiring Prolonged Intensive Care Admission at a Tertiary Centre: A Retrospective Cohort Study.” ANZ journal of surgery (2026). PMID: 41823127 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [92]
Cao Y, Li W, Peng P et al.. “Development and validation of an early prediction model for hypertriglyceridaemic severe acute pancreatitis: a retrospective study.” PeerJ (2026). PMID: 41584837 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [93]
Xu H, Zhang Z, Yang Y et al.. “Partial hepatectomy for pancreatic-origin hepatic abscess with intracystic hemorrhage following severe acute pancreatitis: a case report.” Frontiers in medicine (2026). PMID: 41868209 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [94]
Iacob A, Balan GG, Blaj M et al.. “Fungal Infections in Severe Acute Pancreatitis: Insights from a Case Series.” Journal of clinical medicine (2026). PMID: 41598727 ↗
L4CASE_REPORTCited in: Supportive Care and Complication Management - [95]
Tsuyama T, Suenaga S, Suehiro H et al.. “Lumen-apposing metal stent for peripancreatic fluid collection contributes to early improvement of nutritional status: A multicenter retrospective study (YCR-P001).” Medicine (2026). PMID: 41824843 ↗
L2bCOHORTCited in: Supportive Care and Complication Management - [96]
Zhang X, Peng K, Peng Y et al.. “Serum GAS6 is useful biomarker for identifying patients with severe acute pancreatitis within 24 h of admission: a multi-cohort analysis of 869 patients.” Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] (2026). PMID: 41956867 ↗
L5OTHERCited in: Supportive Care and Complication Management - [97]
Feng H, Wang P, He W et al.. “Development and interpretable machine learning models for classification of pancreatic pseudocyst risk in acute pancreatitis.” Frontiers in digital health (2026). PMID: 41924180 ↗
L5OTHERCited in: Supportive Care and Complication Management - [98]
Zhu P, Fang W, Tu H. “Development and validation of a nomogram model for predicting unplanned readmission in patients with acute pancreatitis.” Frontiers in endocrinology (2026). PMID: 41890191 ↗
L5OTHERCited in: Supportive Care and Complication Management - [99]
Lu H, Shen H, Cui J et al.. “Rhein attenuates severe acute pancreatitis-associated intestinal injury through PPARγ regulating macrophage activation.” Chinese medical journal (2026). PMID: 41859859 ↗
L5OTHERCited in: Supportive Care and Complication Management - [100]
Pauw HS, Schwarz R, Beij A et al.. “Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics.” The Journal of antimicrobial chemotherapy (2026). PMID: 41808660 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [101]
Kitagawa K, Asada S, Hanatani JI et al.. “Multi-Hole Self-Expandable Metallic Stent for Malignant Distal Biliary Obstruction: A Literature Review.” Journal of clinical medicine (2026). PMID: 41753098 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [102]
Fernandez Y Viesca M, Hadefi A, Otero Sanchez L et al.. “Risk Factors Associated with the Emergence of Multidrug-Resistant Bacteria and Fungal Infections in Walled-Off Pancreatic Necrosis.” Antibiotics (Basel, Switzerland) (2026). PMID: 41750517 ↗
L5OTHERCited in: Supportive Care and Complication Management - [103]
Yamashita Y, Kitano M. “EUS-guided pancreatic duct drainage-technical tips and outcomes: narrative review.” Therapeutic advances in gastroenterology (2026). PMID: 41732329 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management - [104]
Ma S, Qin J, Luan J et al.. “Targeting mitochondrial phosphatase PGAM5 alleviates ferroptosis and acute pancreatitis by upregulating NRF2-mediated FSP1 expression.” Cell death & disease (2026). PMID: 41723122 ↗
L5OTHERCited in: Supportive Care and Complication Management - [105]
Siriwardena AK. “A Practical Guide to the Roles of Procalcitonin Measurement in Patients with Acute Pancreatitis.” Journal of clinical medicine (2026). PMID: 41682834 ↗
L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management